GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Remus Pharmaceuticals Ltd (NSE:REMUS) » Definitions » Net Income Including Noncontrolling Interests

Remus Pharmaceuticals (NSE:REMUS) Net Income Including Noncontrolling Interests : ₹384 Mil (TTM As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Remus Pharmaceuticals Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Remus Pharmaceuticals's Net Income Including Noncontrolling Interests for the six months ended in Mar. 2025 was ₹196 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was ₹384 Mil.

Remus Pharmaceuticals Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Remus Pharmaceuticals's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Remus Pharmaceuticals Net Income Including Noncontrolling Interests Chart

Remus Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar24 Mar25
Net Income Including Noncontrolling Interests
8.12 10.26 33.86 242.70 384.20

Remus Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Sep23 Mar24 Sep24 Mar25
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial - 56.48 186.22 187.92 196.28

Remus Pharmaceuticals Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹384 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remus Pharmaceuticals Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Remus Pharmaceuticals's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Remus Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Remus Pharmaceuticals Ltd (NSE:REMUS) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
NSE:DENTALKART BOM:544353 BOM:544143 BOM:536565 BOM:530697 BOM:543500 BOM:531240 BOM:523896 MCK COR CAH ASX:SIG HSIC SHSE:601607 HKSE:01099 SHSE:600332 XSWX:GALE MIL:AMP NZSE:EBO SHSE:600998
Traded in Other Exchanges
N/A
Address
Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054
Website
https://www.remuspharma.com
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.

Remus Pharmaceuticals Headlines

No Headlines